𝛼SK or Searchbullish
Island Pharmaceuticals Ltd - Second manufacturing campaign of Galidesivir for outbreak
SUMMARY
- Island Pharmaceuticals Ltd (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases.
- ILA has commissioned a second manufacturing campaign of GMP-grade Galidesivir with PI Health Sciences, which will increase its available inventory to approximately 700-800 treatment courses in Q4 CY26.
- This inventory will improve ILA’s ability to rapidly respond to the active Bundibugyo Ebola outbreak, deploy Galidesivir under the MEURI framework and engage with government and biodefence agencies without waiting for a new manufacturing campaign.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Island Pharmaceuticals Ltd - Second manufacturing campaign of Galidesivir for outbreak24 Aug 2026
x